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Expanding the Psoriasis Disease Profile: Interrogation
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James G. Krueger1
Psoriasis is a complex disease with an expanding definition of its pathological features. We sought to expand/
refine the psoriasis transcriptome using 85 paired lesional and non-lesional samples from a cohort of patients
with moderate-to-severe psoriasis vulgaris who were not receiving active psoriasis therapy. This new analysis
identified 4,175 probe sets (representing 2,725 unique known genes) as being differentially expressed in psoriasis
lesions compared with matched biopsies of non-lesional skin when the following criteria were applied:42-fold
change and false discovery rate o0.05. These probe sets represent the largest and most comprehensive set of
genes defining psoriasis at the molecular level and within the previously unidentified genes, a link to functional
pathways associated with metabolic diseases/diabetes and to cardiovascular risk pathways is identified. In
addition, we profiled the serum of moderate-to-severe psoriatics compared with healthy controls to assess the
overlap of overexpressed lesional genes with overexpressed systemic proteins. We identified linkage of
functional pathways in lesional skin associated with metabolic diseases/diabetes and cardiovascular risk with
those pathways overexpressed in the serum, suggesting a potential linkage between altered gene transcription in
the skin and comorbidities commonly seen in patients with moderate-to-severe psoriasis.
Journal of Investigative Dermatology (2012) 132, 2552–2564; doi:10.1038/jid.2012.184; published online 5 July 2012
INTRODUCTION
A molecular definition of disease requires elucidation of
genetic, genomic, metabolic, and proteomic disease ele-
ments. Disease profiles are then built upon multiple datasets
and are influenced by many factors including disease
severity, matrices profiled, concomitant medications, techni-
cal differences in collection, and patient characteristics.
The pathological definition of psoriasis has greatly
expanded over several decades. Before 2000, application of
conventional methods produced essential information
about keratinocytes, blood vessels, and immune-related
cells in psoriatic lesions, ultimately leading to the identifica-
tion of ‘‘unique’’ psoriasis proteins, e.g., psoriasin (S100A7;
Borglum et al., 1995; Hardas et al., 1996) and c-3 antigen
(Mansbridge et al., 1984). Starting in 2001, however, a
more holistic definition of psoriasis pathology in diseased
tissue could be pursued via a broad genomic approach
comparing messenger RNA (mRNA) expression between
psoriatic lesions and ‘‘non-lesional’’ background skin of the
same patient.
The first list of psoriasis-associated genes (transcriptome),
using an early Affymetrix platform, encompassed 159 genes
(Oestreicher et al., 2001). From these data, a process of
ordering altered gene expression into functional pathways
controlled by ‘‘master’’ cytokines or transcription factors was
begun. Subsequent gene array studies identified varied
dysregulated pathways encompassing many hundreds of
genes (Zhou et al., 2003; Gudjonsson, 2007; Yao et al.,
2008; Sua´rez Farin˜as et al., 2010). This growing list of
differentially expressed genes (DEGs), or ‘‘psoriasis transcrip-
tome,’’ has been driven by several factors, including: (1)
development of higher-density arrays that now encompass all
known human transcripts, (2) technological improvements in
biochemical methods for determining complementary DNA
transcripts, (3) assessment of larger patient cohorts, yielding
greater statistical power after adjustments for multiplicity of
testing, and (4) ongoing improvements in statistical methods
for analyzing whole-genome transcripts. To date, Gudjonsson
et al. (2010) have studied the largest set of psoriasis patients
(n¼58) for transcriptome profiling, yielding identification of
1,326 DEGs.
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In parallel with gene expression profiling, considerable
effort has been made to define disease inheritance through
conventional genetic methods and genome-wide association
studies (Zhang et al., 2009; Elder et al., 2010; Ellinghaus
et al., 2010; Sun et al., 2010). These studies have identified
420 risk alleles/genes contributing to the risk of acquiring
psoriasis. However, little is currently known about the
association between the risk alleles and altered gene function
and/or associated biological processes.
Metabolic and proteomic profiling of psoriasis has been
much more limited. Many publications focus on the
measurement of a small number of circulating proteins with
no systematic profiling of circulating/lesional proteins.
However, a recent report that employed proteomics to
profile lesional psoriatic skin (Piruzian et al., 2010)
confirmed production of keratin and S100 proteins pre-
viously known to be upregulated at the transcript level.
Recent studies have shown that psoriasis comorbidities (e.g.,
cardio-metabolic) significantly impact patient health, and it
has been hypothesized that inflammatory products could
potentially be synthesized in the skin and released into
systemic circulation by diffusion through cutaneous en-
dothelium (Davidovici et al, 2010). Hence, we undertook a
protein profiling effort for more than 90 serum proteins to
understand the overlap between lesional overexpression of
genes and systemically detectable proteins. In doing so, we
also expanded/refined the psoriasis skin transcriptome to
4,175 transcripts in a cohort of 85 paired lesional and non-
lesional samples obtained from patients with moderate-to-
severe psoriasis vulgaris not receiving active psoriasis
treatment. Understanding the ‘‘mechanics’’ of psoriasis, not
only in the skin but also in the circulation, is important
because many of the previously unidentified gene products
from this analysis are linked to functional pathways
associated with metabolic diseases/diabetes and to cardio-
vascular risk pathways, suggesting a potential linkage
between altered gene transcription in the skin and comorbid
diseases that are commonly seen in patients with moderate-
to-severe psoriasis.
RESULTS
Patient cohorts
Baseline demographic characteristics for 89 psoriatic patients
with skin biopsy samples, as well as 149 psoriatic patients
and 162 healthy subjects with samples for serum protein
analyses, are provided in Table 1. Of the 89 patients in the
skin biopsy substudy, 62 contributed serum samples to the
serum protein analyses. Baseline characteristics for the
patients providing serum samples are summarized in
Supplementary Table S1 online. Healthy subjects were more
likely to be non-Caucasian and current smokers than psoriatic
patients (Po0.0001). Among the patients with moderate-to-
severe psoriasis, B30% of their body surface area had
psoriasis involvement, and the average baseline psoriasis area
and severity index scores were B21(±10.2) (Table 1).
The transcriptome of ‘‘moderate-to-severe’’ psoriasis plaques
contains 4,175 differentially expressed transcripts
We identified 4,175 probe sets as being differentially
expressed in psoriasis lesions versus non-lesional matched
biopsies when defined by 42-fold change (FCH) and false
discovery rate (FDR)o0.05. A heatmap of the DEGs is shown
in Figure 1a. The top 50 genes over- or under-expressed in
psoriatic lesions are listed in Tables 2a and 2b, respectively.
All DEGs are listed in Supplementary Table S2 online. Tables
2a and 2b also specify whether identified genes are regulated
in keratinocytes by the cytokines tumor necrosis factor-a
(TNF), IL-17, or IFN-g, which are key mediators of
inflammation in psoriasis. The S100A12 gene, a highly
inflammatory molecule that binds to the receptor for
advanced glycation end products, and is increased in
inflammatory dendritic cells and keratinocytes in response
to inflammatory cytokines such as IL-17, TNF, and IFN-g
(Nograles et al., 2008; Zaba et al., 2010) exhibited the largest
increase in expression.
IL-17 and TNF are now known to exert additive and
synergistic effects on keratinocytes to modulate gene expres-
sion (Chiricozzi et al., 2011). Interestingly, 60% of the top 20
upregulated genes (Table 2a) have additive (A) or synergistic
Table 1. Baseline demographic characteristics of 89 psoriasis patients with lesional and non-lesional skin biopsy
samples, as well as 149 psoriasis patients and 162 healthy control subjects included in serum protein analysis
Psoriasis patients (n=89) Psoriasis patients (n=149) Healthy controls (n=162)
Age (years) 44.6±13.1 46.3±12.8 42.6±14.0
Male 66 (77.5%) 114 (76.5%) 89 (59.3%)
Caucasian 75 (84.3%) 133 (89.3%) 29 (22.5%)*
Current smoker 36 (40.4%) 50 (33.6%) 68 (62.4%)*
Obese 47 (52.8%) 73 (49.3%) 35(32.1%)**
Body surface area with psoriasis (%) 30±20.5 29.5±18.6 —
Psoriasis area and severity index score 21.5±10.8 21.3±9.0 —
Psoriatic arthritis 19 (21.3%) 38 (25.5%) —
Data shown are number (%) of patients or mean±standard deviation.
*Po0.0001.
**P=0.0026.
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(S) responses to IL-17 and TNF, suggesting the particular
importance of these cytokines in creating the ‘‘top’’
molecular profile of psoriasis. From comparing psoriatic
DEGs with genes differentially regulated in human keratino-
cytes by cytokines, we find 231 genes of TNF signaling, 481
genes of IFN-g signaling, 29 genes of IL-17 signaling, 10
genes of IL-22 signaling, and 144 genes that have additive or
synergistic responses to IL-17 and TNF. Thus, X20% of the
overall psoriasis transcriptome is concordant with gene
alterations produced in cultured keratinocytes by defined
cytokines. In addition, this gene set potentially reflects the
direct effect of inflammatory cytokines on the disease
phenotype.
Using gene array, we did not detect increased expression
of many T-cell-produced cytokines, e.g., IFN-g, IL-17 or IL-
22, which consistently have been increased in psoriasis
plaques, when measured by real-time reverse transcriptase
PCR (RT-PCR) methods (Sua´rez Farin˜as et al., 2010). Hence,
we also measured a set of disease-related cytokine mRNAs by
RT-PCR in lesional and non-lesional tissues from this group of
patients (Supplementary Table S3 online). As expected, we
detected much greater expression of mRNAs encoding IL-23
(p40 and p19 subunits), IFN-g, IL-17, and IL-22 in lesional
versus non-lesional biopsies, with expression in psoriasis
lesions ranging from 3.6-fold to 120-fold (P-values ranging
from 1011 to 1029) when measured by RT-PCR, but
generally o2-fold on gene arrays. Hence, despite a large
dynamic range to measure gene expression (16 logs),
microarrays are unreliable for detecting quantitative differ-
ences in expression of these primary cytokine mRNAs
generally found in low (B2 log values) levels (Sua´rez Farin˜as
et al., 2010).
Low-density card confirmation
We performed extensive confirmation of 50 DEGs by
quantitative RT-PCR (Table 3, Figure 1b), 42 of which were
confirmed (Po0.05, FCH42; note that seven genes were not
confirmed, and one gene (ADAM10) was borderline). RT-PCR
and gene array findings showed a high degree of correlation,
with a Pearson’s correlation coefficient of 0.773 (Po1011)
for the magnitude of fold changes observed by these methods
(Figure 1b). Linear regression analysis shows a slight
compression of FCHs by gene array (18% reduction), a
known feature of this technique (MAQC Consortium et al.,
2006).
Comparison with other psoriasis transcriptomes
To our knowledge, this study identified the largest set of
DEGs in psoriasis vulgaris lesions, with more than 2,400
transcript differences that were not detected in two other
recent studies employing transcriptional profiling of relatively
large patient groups that also employed HGU133plus2 chips
(Supplementary Table S4 online). Using a Venn diagram to
plot the similarities/differences in mRNA expression between
this study versus those reported by Gudjonsson et al. (2010)
and Yao et al. (2008) (Figure 1c), we saw significant overlap
of DEGs detected across the studies, with strong overlap
within the most highly upregulated or downregulated genes
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Figure 1. The transcriptome of moderate-to-severe psoriasis. (a) Heatmap
of differentially expressed genes (DEGs). Unsupervised clustering of lesional
(LS) versus non-lesional (NL) DEGs. (b) Scatter plot of the estimated
fold change (log2 scale) by real-time reverse transcriptase PCR (RT-PCR,
x-axis) and gene array (y-axis) for a selected group of 50 genes (see Table 3).
Gray lines outline the two-fold change (FCH) regions. Stars and bullets
represent two different low-density cards. Red shows confirmed genes.
Classical linear regression analysis (red line) shows a slight compression of
FCHs by gene array. Pearson’s (r) and Spearman’s (r) correlation values
are presented along with P-values. (c) Venn diagram comparing genes
(blue numbers: downregulated genes; red numbers: upregulated genes)
identified in this study with those of two published studies employing the
same Affymetrix HG U133 Plus 2.0 arrays using the same cutoff criteria (false
discovery rate o0.05, FCH42).
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Table 2a. The top 50 unique genes upregulated in lesional skin compared with non-lesional skin biopsy samples
obtained at baseline from 85 patients with moderate-to-severe psoriasis (FDR Po0.05 and FCH 42)
Mean
expression in
skin samples
Probe set ID
Gene
symbol Gene title
Fold change
(lesional vs.
non-lesional)
Non-
lesional Lesional
Cytokine
regulation1
205863_at S100A12 S100 calcium–binding protein A12 889.1 2.72 12.52 IL-17, TNF-a, IFN-g, A
211906_s_at SERPINB4 Serpin peptidase inhibitor, clade B
(ovalbumin), member 4
740.44 3.76 13.30 IL-17, S
205513_at TCN1 Transcobalamin I (vitamin B12–binding
protein, R binder family)
400.17 2.95 11.60
232220_at S100A7A S100 calcium–binding protein A7A 287.22 5.15 13.32 S
220664_at SPRR2C Small proline-rich protein 2C
(pseudogene)
243.3 3.62 11.55 IL-17, A
205660_at OASL 2’-5’-Oligoadenylate synthetase-like 238.28 3.15 11.04 IFN-g
207602_at TMPRSS11D Transmembrane protease, serine 11D 199.6 2.89 10.53 S
1569555_at GDA Guanine deaminase 168.79 3.44 10.84
210663_s_at KYNU Kynureninase (L-kynurenine hydrolase) 153.53 2.75 10.02 TNF-a, S
207367_at ATP12A ATPase, H+/K+ transporting, nongastric,
a-polypeptide
148.59 3.93 11.15 A
220528_at VNN3 Vanin 3 144.45 2.23 9.40 S
210413_x_at SERPINB3/SERPINB4 Serpin peptidase inhibitor, clade B
(ovalbumin), member 3/serpin peptidase
inhibitor, clade B (ovalbumin),
member 4
136.5 6.86 13.95
206561_s_at AKR1B10 Aldo-keto reductase family 1, member
B10 (aldose reductase)
114.33 6.19 13.03
202859_x_at IL8 interleukin 8 105.05 2.82 9.54 IL-17, TNF-a, S
205783_at KLK13 Kallikrein-related peptidase 13 94.62 4.16 10.73
219554_at RHCG Rh family, C glycoprotein 74.17 5.51 11.72 IL-17, TNF-a, A
204470_at CXCL1 Chemokine (C–X–C motif) ligand 1
(melanoma growth stimulating activity,
alpha)
72.33 2.45 8.63 IL-17, TNF-a, IFN-g, S
1554914_at PLA2G4D Phospholipase A2, group IVD (cytosolic) 66.91 2.75 8.81
205476_at CCL20 Chemokine (C–C motif) ligand 20 64.89 2.93 8.95 IL-17, TNF-a, S
219403_s_at HPSE Heparanase 63.46 6.14 12.13
216258_s_at SERPINB13 Serpin peptidase inhibitor, clade B
(ovalbumin), member 13
61.38 3.25 9.19
210164_at GZMB Granzyme B (granzyme 2, cytotoxic
T-lymphocyte-associated serine
esterase 1)
60.46 2.93 8.85
232074_at PRSS27 Protease, serine 27 56.4 4.33 10.15
204733_at KLK6 Kallikrein-related peptidase 6 51.71 6.79 12.48
205844_at VNN1 Vanin 1 50.72 4.41 10.08
210038_at PRKCQ Protein kinase C, theta 48.3 2.54 8.14
206912_at FOXE1 Forkhead box E1 (thyroid transcription
factor 2)
46.38 2.92 8.45 S
239430_at IGFL1 IGF-like family member 1 46.06 4.77 10.30
220322_at IL1F9 Interleukin 1 family, member 9 45.99 7.82 13.34 IL-17, TNF-a, IFN-g, A
209719_x_at SERPINB3 Serpin peptidase inhibitor, clade B
(ovalbumin), member 3
45.81 8.96 14.48 IFN-g(), S
212531_at LCN2 Lipocalin 2 45.74 7.96 13.47 IL-17, TNF-a, IFN-g(), A
Table 2a continued in the following page
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using the same FDR (o0.05) and FCH (42) cutoff criteria. As
discussed previously (Sua´rez Farin˜as et al., 2005a; Sua´rez
Farin˜as and Magnasco, 2007), Venn diagrams often suggest
overall results of studies are significantly discordant because
arbitrary thresholds of differences in gene expression lead to
‘‘absolute’’ calls of a difference in expression. Using more
recently published methods (Sua´rez Farin˜as et al., 2010), we
calculated enrichment scores for the lists of Yao and colleagues
(scores of 0.92 and 0.83 for upregulated and downregulated
genes, respectively) and Gudjonsson and colleagues (scores of
0.94 and 0.89 for upregulated and downregulated genes,
respectively; Supplementary Table S5 online). These results
indicate very high concordance of the psoriatic genomic
phenotype, as defined by gene expression, across the three
studies. The present study has detected the largest number of
DEGs, to our knowledge, that can be used to define ‘‘moderate-
to-severe’’ psoriasis at the molecular level.
Expanded psoriasis transcriptome analysis
We utilized Ingenuity Pathway Analysis (IPA) to identify
biological functions and pathways relevant to the psoriasis
transcriptome and to more thoroughly understand genes
uniquely identified in this study (Supplementary Table S4
online)
Within the ‘‘unique’’ set, IPA identified cancer as the most
significantly enriched biological function (Po1012), fol-
lowed by endocrine system disease, gastrointestinal disease,
genetic disorders, metabolic disease, and cardiovascular
disease (Po107 in all cases; Supplementary Figure S1a
online). The genetic disorder category includes several
subcategories that were also enriched in this unique DEG
subset, including coronary artery disease (162 genes,
Po107), and Crohn’s disease or inflammatory bowel
disease (140 genes, Po104). The endocrine system and
metabolic disease category also encompasses the previously
Table 2a. Continued
Mean
expression in
skin samples
Probe set ID
Gene
symbol Gene title
Fold change
(lesional vs.
non-lesional)
Non-
lesional Lesional
Cytokine
regulation1
224204_x_at ARNTL2 Aryl hydrocarbon receptor nuclear
translocator-like 2
43.67 4.03 9.48
213797_at RSAD2 Radical S-adenosyl methionine domain
containing 2
41.39 5.03 10.40 IFN-g
233504_at C9orf84 Chromosome 9 open reading frame 84 40.75 3.70 9.05
227735_s_at C10orf99 Chromosome 10 open reading frame 99 40.71 7.78 13.13
203535_at S100A9 S100 calcium–binding protein A9 40.71 9.25 14.60 IL-17, TNF-a, IFN-g, A
226698_at FCHSD1 FCH and double SH3 domains 1 39.37 5.42 10.72
220249_at HYAL4 Hyaluronoglucosaminidase 4 39.25 4.25 9.55
202134_s_at WWTR1 WW domain containing transcription
regulator 1
36.95 4.69 9.89 TNF-a(), IFN-g()
206134_at ADAMDEC1 ADAM-like, decysin 1 36.28 4.32 9.50
241994_at XDH Xanthine dehydrogenase 35.21 3.41 8.55 IFN-g
1553434_at CYP4Z2P Cytochrome P450, family 4, subfamily Z,
polypeptide 2 pseudogene
34.49 2.22 7.33
227609_at EPSTI1 Epithelial stromal interaction 1 (breast) 34.32 3.77 8.87
206008_at TGM1 Transglutaminase 1 (K polypeptide
epidermal type I, protein-glutamine-g-
glutamyltransferase)
34.05 5.62 10.71 TNF-a, IFN-g, A
219691_at SAMD9 Sterile a-motif domain containing 9 33.57 4.43 9.50 IFN-g
240304_s_at TMC5 Transmembrane channel-like 5 33.52 3.11 8.18
221107_at CHRNA9 Cholinergic receptor, nicotinic, a-9 32.35 3.19 8.21
204465_s_at INA Internexin neuronal intermediate
filament protein, alpha
31.67 3.85 8.83
239586_at FAM83A Family with sequence similarity 83,
member A
31.29 5.43 10.40
209773_s_at RRM2 Ribonucleotide reductase M2
polypeptide
31.19 5.71 10.67 IFN-g()
Abbreviations: FCH, fold change; FDR, false discovery rate; TNF, tumor necrosis factor.
1Genes that are induced by IL-17, IFN-g, and TNF-a in keratinocytes and yield a synergistic (S) or additive (A) effect between IL-17 and TNF on keratinocytes
(Nograles et al., 2008; Chiricozzi et al., 2011).
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Table 2b. The top 50 unique genes downregulated in lesional skin compared with non-lesional skin biopsy samples
obtained at baseline from 85 patients with moderate-to-severe psoriasis (FDR Po0.05 and FCH42)
Mean
expression in
skin samples
Probe set ID Gene symbol Gene title
Fold change
(lesional vs.
non-lesional)
Non-
lesional Lesional
Cytokine
regulation1
217059_at MUC7 Mucin 7, secreted 26.11 7.62 2.91
241412_at BTC Betacellulin 25.6 7.59 2.91
205404_at HSD11B1 Hydroxysteroid (11-b) dehydrogenase 1 24.61 9.23 4.61 TNF-a, IFN-g
205979_at SCGB2A1 Secretoglobin, family 2A, member 1 22.46 9.23 4.74
229477_at THRSP Thyroid hormone responsive (SPOT14
homolog, rat)
22.24 8.64 4.16
204712_at WIF1 WNT inhibitory factor 1 21.11 9.21 4.81
214053_at ERBB4 V-erb-a erythroblastic leukemia viral oncogene
homolog 4 (avian)
17.98 6.85 2.68
227174_at WDR72 WD repeat domain 72 17.24 7.17 3.07
205883_at ZBTB16 Zinc-finger and BTB domain containing 16 16.84 8.06 3.98
208962_s_at FADS1/FADS3 Fatty acid desaturase 1/fatty acid desaturase 3 15.95 9.84 5.84 IFN-g()
229151_at SLC14A1 Solute carrier family 14 (urea transporter),
member1 (Kidd blood group)
15.86 7.46 3.47
204607_at HMGCS2 3-Hydroxy-3-methylglutaryl-Coenzyme A
synthase 2 (mitochondrial)
15.36 8.08 4.14
207430_s_at MSMB Microseminoprotein, b- 13.47 6.99 3.24
239929_at PM20D1 Peptidase M20 domain containing 1 13.28 10.05 6.32
214240_at GAL Galanin prepropeptide 12.5 7.35 3.71 TNF-a(), IFN-g()
1559097_at C14orf64 Chromosome 14 open reading frame 64 11.89 6.35 2.78
230197_s_at TPPP Tubulin polymerization promoting protein 11.11 9.72 6.24
205325_at PHYHIP Phytanoyl-CoA 2-hydroxylase interacting
protein
10.28 8.44 5.08
234980_at TMEM56 Transmembrane protein 56 10.27 6.22 2.86
235278_at MACROD2 MACRO domain containing 2 9.55 6.34 3.08
205029_s_at FABP7 Fatty acid–binding protein 7, brain 9.42 9.31 6.07
220801_s_at HAO2 Hydroxyacid oxidase 2 (long chain) 9.39 5.75 2.52
205030_at FABP7 Fatty acid–binding protein 7, brain 9.29 10.33 7.12
213920_at CUX2 Cut-like homeobox 2 9.26 5.93 2.72
1555318_at HIF3A Hypoxia-inducible factor 3, a-subunit 9.25 10.45 7.24
221795_at NTRK2 Neurotrophic tyrosine kinase, receptor, type 2 9.22 8.41 5.20
234513_at ELOVL3 Elongation of very long-chain fatty acids (FEN1/
Elo2, SUR4/Elo3, yeast)-like 3
9.21 5.84 2.64
201596_x_at KRT18 Keratin 18 9.17 8.60 5.40
227803_at ENPP5 Ectonucleotide pyrophosphatase/
phosphodiesterase 5 (putative function)
8.93 6.45 3.29
208331_at BPY2 Basic charge, Y-linked, 2 8.8 6.03 2.89
222102_at GSTA3 Glutathione S-transferase A3 8.75 10.04 6.91
223836_at FGFBP2 Fibroblast growth factor–binding protein 2 8.65 9.48 6.37
213661_at DKFZP586H2123 Regeneration-associated muscle protease 8.64 10.15 7.04
232602_at WFDC3 WAP four-disulfide core domain 3 8.62 8.27 5.16
Table 2b continued in the following page
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identified association with non-insulin-dependent diabetes
(185 genes, Po108), as well as a broader 272-gene
subcategory associated with diabetes (Po108). The
cardiovascular disease category includes a subcategory of
139 genes, including renin associated with hypertension
(Po107) and atherosclerosis (170 genes, Po107).
Surprisingly, the metabolic and cardiovascular associations
were more highly significant than the cell cycle and
inflammatory disease categories, although these were also
significant in IPA.
An IPA of the whole psoriasis transcriptome identified in
this study yielded dermatological conditions (379 genes,
Po1070), genetic disorder (361 genes, Po1074), cancer
(968 genes, Po1064), and gastrointestinal disease (893
genes, Po1026) as the four top associations, the subcate-
gories of which contain the links to non-insulin-dependent
diabetes, coronary artery disease, and inflammatory bowel
disease previously discussed. Within the inflammatory,
immune response and cardiovascular disorders categories,
interesting previously unreported psoriasis genes included
cytotoxic T-lymphocyte antigen (CTLA)-4, Toll-like receptor
(TLR)-3, and renin. We confirmed via immunohistochemistry
that protein products of these genes were expressed at high
levels in psoriasis plaques (Figure 2). CTLA4 staining was
observed on keratinocytes and dermal cells, whereas TLR3
was expressed mostly on keratinocytes. In contrast, renin was
expressed at very high levels by scattered cells in the
papillary and upper reticular dermis. Among the canonical
pathways collection (Supplementary Figure S1d online), IPA-
identified metabolism involved pathways such as arthero-
sclerosis signaling, PPARa activation, RAR activation, reni-
n–angiotensin signaling, and leptin signaling (Po102 all
cases). The enrichment of PPARa/RAR as well as IL-1-
mediated inhibition of RXR agrees with data presented by
Romanowska and colleagues (2010). Additionally, 3 of the
top 10 pathways were macrophage-related pathways and
included Fcc receptor–mediated phagocytosis in macro-
phages and monocytes, and iNOS production in macro-
phages.Wnt and FGF signaling pathways were not significant
in our analysis. IPA also identified transcription factors
activated or in our transcriptome. Of relevance, downstream
genes regulated by STAT1, 2, and 3 were found to be
activated. Interestingly, the transcription factor NROB2 is
implicitly activated, and its function of downregulating
targeting genes could possibly explain suppressed PPARa
and RAR network alterations.
Table 2b. Continued
Mean
expression in
skin samples
Probe set ID Gene symbol Gene title
Fold change
(lesional vs.
non-lesional)
Non-
lesional Lesional
Cytokine
regulation1
201650_at KRT19 Keratin 19 8.35 10.67 7.61 TNF-a, IFN-g
239246_at FARP1 FERM, RhoGEF (ARHGEF), and pleckstrin
domain protein 1 (chondrocyte-derived)
8.26 8.59 5.55 TNF-a
231859_at C14orf132 Chromosome 14 open reading frame 132 8.18 7.33 4.30
207955_at CCL27 Chemokine (C–C motif) ligand 27 8.14 12.55 9.52 TNF-a
1564786_at LOC338667 Hypothetical protein LOC338667 7.82 7.36 4.40
1557474_at LOC284578 Hypothetical protein LOC284578 7.81 5.66 2.69
214598_at CLDN8 Claudin 8 7.67 10.82 7.88
204416_x_at APOC1 Apolipoprotein C-I 7.62 10.28 7.35
231535_x_at ROPN1 Ropporin, rhophilin-associated protein 1 7.58 6.59 3.66
239304_at MFSD4 Major facilitator superfamily domain
containing 4
7.43 7.42 4.53
204032_at BCAR3 Breast cancer anti-estrogen resistance 3 7.37 8.00 5.11
220425_x_at ROPN1/ROPN1B Ropporin, rhophilin-associated protein 1/
ropporin, rhophilin associated protein 1B
7.28 7.82 4.96
224646_x_at H19 H19, imprinted maternally expressed transcript 7.19 11.01 8.16
205529_s_at RUNX1T1 Runt-related transcription factor 1; translocated
to, 1 (cyclin D-related)
7.1 8.10 5.27
228943_at MAP6 Microtubule-associated protein 6 7.08 5.61 2.79
1560741_at SNRPN Small nuclear ribonucleoprotein polypeptide N 7.06 6.85 4.03
Abbreviations: FCH, fold change; FDR, false discovery rate; TNF, tumor necrosis factor.
1Genes that are induced by IFN-g or TNF-a on keratinocytes (Nograles et al., 2008).
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Table 3. Confirmation of genes by RT-PCR testing and comparison with gene microarray results
Real-time reverse transcriptase PCR Gene microarray
Gene
symbol
Fold change
(lesional vs.
non-lesional)
Log2
(fold change) P-value
Fold change
(lesional vs.
non-lesional)
Log2
(fold change)
False
discovery rate
Differentially expressed genes
1 IL19 1359.74 10.41 3.43 1017 18.29 4.19 o1015
2 DEFB4 385.00 8.59 3.07 1019 15.68 3.97 o1015
3 TNIP3 341.29 8.41 1.73 109 23.18 4.53 o1015
4 SERPINB3 121.92 6.93 9.00 1019 45.81 5.52 o1015
5 SPRR2C 33.16 5.05 7.55 1014 243.3 7.93 o1015
6 HPSE 32.35 5.02 8.79 1012 63.46 5.99 o1015
7 OASL 29.68 4.89 1.39 1013 238.28 7.90 o1015
8 IVL 13.95 3.80 1.29 107 4.63 2.21 o1015
9 OAS2 12.95 3.70 7.54 1010 22.19 4.03 o1015
10 PMCH 12.45 3.64 1.19 105 2.84 1.51 o1015
11 CTLA4 11.21 3.49 6.05 105 16.31 4.03 o1015
12 HERC6 10.67 3.42 3.40 106 16.13 4.01 o1015
13 CXCL10 9.42 3.24 7.79 107 24.66 4.62 o1015
14 CXCL11 9.40 3.23 1.18 105 2.06 1.04 4.17106
15 IL1B 8.80 3.14 7.61 107 7.04 2.82 o1015
16 MX1 8.44 3.08 2.19 108 8.71 3.12 o1015
17 NAMPT 5.93 2.57 7.75 108 20.59 4.36 o1015
18 STAT1 5.81 2.54 4.37 107 11.79 3.56 o1015
19 CARHSP1 5.78 2.53 3.73 109 7.58 2.92 o1015
20 MMP9 5.56 2.47 8.38 104 2.54 1.34 4.56109
21 CCNE1 5.54 2.47 5.33 105 5.71 2.51 o1015
22 CXCL9 5.39 2.43 1.42 105 15.68 3.97 o1015
23 CCL18 4.67 2.22 4.64 105 4.77 2.25 1.77109
24 STEAP4 4.05 2.02 3.10 105 8.33 3.06 o1015
25 CCNB1 4.00 2.00 7.16 106 8.74 3.13 o1015
26 S100P 3.63 1.86 5.24 104 3.2 1.68 7.601014
27 CCNA2 3.62 1.85 2.34 104 14.28 3.84 o1015
28 CEBPD 2.03 1.02 1.34 102 7.43 2.89 o1015
29 ADAM10 1.58 0.66 7.64 102 4.41 2.14 o1015
30 SNCA 1.27 0.35 4.99 101 3.71 1.89 o1015
31 NR1H3 1.61 0.69 1.74 102 2.69 1.43 o1015
32 NTRK2 1.68 0.75 5.43 102 9.22 3.20 o1015
33 KRT33A 1.84 0.88 4.28 101 2.19 1.13 6.00104
34 CD207 2.09 1.06 1.75 101 2.96 1.57 2.041011
35 KRT73 2.14 1.10 8.42 103 2.17 1.12 6.86105
36 KRT18 2.17 1.12 3.87 104 9.17 3.20 o1015
37 LPL 2.21 1.14 8.42 103 6.25 2.64 7.021013
38 KRT19 2.45 1.29 1.28 103 8.35 3.06 o1015
39 ACTA2 2.75 1.46 7.41 104 3.69 1.88 o1015
40 APOC1 3.12 1.64 5.55 103 7.62 2.93 o1015
41 MUC1 3.55 1.83 1.51 103 6.10 2.61 2.151011
42 FADS2 5.83 2.54 2.02 102 6.43 2.68 1.291011
Table 3 continued in the following page
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Parallel increases in inflammatory elements in skin and blood
The overexpression of renin, as well as other cardiovascular,
metabolic, and inflammatory markers in the skin, raised the
question of whether these pathways are also dysregulated in
the circulation of psoriatic patients. When profiling the
expression of a 92-protein panel (Supplementary Table S6
online) in this psoriatic population, we detected increased
expression of 12 proteins in the serum of psoriasis patients
versus a control population of healthy individuals; increases
ranged from 1.25-fold to 43.5-fold (P-values of 105–1050;
Table 3. Continued
Real-time reverse transcriptase PCR Gene microarray
Gene
symbol
Fold change
(lesional vs.
non-lesional)
Log2
(fold change) P-value
Fold change
(lesional vs.
non-lesional)
Log2
(fold change)
False
discovery rate
43 FADS1 5.96 2.58 6.69 104 15.95 4.00 2.271015
Borderline genes
44 IL22 168.03 7.39 5.67 1014 1.19 0.25 2.56102
45 S100A7 44.94 5.49 2.01 1012 1.62 0.70 o1015
46 CD69 2.43 1.28 1.82 102 1.71 0.77 1.62106
47 CD209 1.49 0.57 3.52 101 1.58 0.66 2.40103
48 JAK2 1.46 0.55 1.42 101 1.47 0.56 2.21107
49 ITGAM 1.15 0.20 7.92 101 1.63 0.70 5.00104
50 ITGAX 1.25 0.32 6.63 101 1.69 0.76 1.49108
Abbreviations: DEGs, differentially expressed genes; RT-PCR, real-time reverse transcriptase PCR.
Genes 1–43 were chosen among those DEGs by microarray analysis, with the exception of gene 29 (ADAM10), which was borderline. Additional borderline
genes (44–50) were also confirmed.
CTLA4 (normal)
TLR3 (normal)
Renin (normal)
a
b
c
Renin (non-lesional) Renin (lesional)
CTLA4 (lesional)CTLA4 (non-lesional)
TLR3 (lesional)TLR3 (non-lesional)
Figure 2. Protein expression of previously unreported genes detected in this transcriptome. Representative immunohistochemistry staining in normal,
non-lesional, and lesional psoriasis skin (n¼ 5). (a) Renin was highly expressed by scattered cells in the papillary and upper reticular dermis mostly in
lesional skin compared with non-lesional and normal skin. (b) Cytotoxic T-lymphocyte antigen (CTLA4) was expressed on keratinocytes and some dermal cells
in lesional skin compared with very little expression on non-lesional skin and none on normal skin. (c) Toll-like receptor (TLR3) was strongly expressed on
keratinocytes of lesional skin compared with a faint expression on normal and non-lesional skin. Scale bar¼ 100mm.
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Table 4). Most of these products are inflammatory cytokines/
chemokines or proteins responsive to cytokines. Each protein
is associated with corresponding increases in mRNA levels in
psoriasis lesions and P-values o0.05 for the mRNA increase
(Table 4). An imbalance in race distribution was observed in
the psoriasis versus healthy control populations; however,
results of analyses conducted with race added as a covariate
indicated no significant effect of race on the expression of
these 12 proteins. Body mass index (BMI) as a covariate did
not significantly affect gene expression for these products, but
within overall serum measures, increased or decreased levels
of some proteins, e.g, leptin and insulin, were affected by
BMI (Supplementary Table S6 online). Also using a more
sensitive assay for IL-17A, we found increased expression in
the blood of psoriasis patients compared with healthy
controls (Supplementary Figure S2 online).
DISCUSSION
Our study findings represent the largest set of DEGs in
psoriasis to date, to our knowledge, and provide the most
comprehensive molecular definition of moderate-to-severe
disease based on lesional skin. This was accomplished using
the same analytical criteria as employed in previously
published studies with smaller sample sizes. We also
expanded the disease definition by profiling serum samples
for differentially regulated proteins and assessing their
dysregulation in lesional skin. Results of gene expression
profiling conducted via gene-set enrichment analysis demon-
strated similarities between this study and previously reports
(Oestreicher et al., 2001; Zhou et al., 2003; Yao et al., 2008).
Also, upregulated genes such as S100A12, SERPINB4/
SERPINB3, and IL-8, and downregulated genes such as
BTC, WIF1, THRSP, and WDR72 are among the top 15
within both our list and that reported by Gudjonsson et al.
(2010). We have also confirmed many upregulated genes
involved in signaling pathways believed to be central in
psoriasis pathogenesis, including the IFN-g, TNF, and IL-17
signaling pathways. Some of the specific upregulated genes
include OASL, CXCL1, STAT-1, and Mx-1 belonging to the
IFN-g signaling pathway; AKR1B10, IL1F9, and CXCL9
belonging to the TNF signaling pathway; and CCL20 and
CXCL8 (IL-8) belonging to the IL-17 signaling pathway
(Haider et al., 2008; Nograles et al., 2008).
In addition, we identified several genes biologically
significant for psoriasis that were previously unreported,
including renin, CTLA4, and TLR3. Renin is a gene involved
in the renin–angiotensin signaling pathway that ultimately
leads to aldosterone release, vasoconstriction, and an
increase in blood pressure, and psoriatic patients have
enhanced plasma renin activity and increased urinary
aldosterone excretion (Ena et al., 1985). The CTLA4 gene,
is one of the genes listed under metabolic disorder and
diabetes in the metabolic disease functional pathway as is
involved in negative regulation of T-cell proliferation as well
as regulatory T-cell differentiation and immune response. In
psoriasis-like murine skin, the induction of T-regulatory cells
Table 4. Increased expression of 12 proteins, as detected by serum and gene microarray assessments, in psoriasis
patients (n=146) versus a control population of healthy individuals (n=162)
Serum measurements Gene array measurements
Symbol Name P-value1
Fold change
(psoriasis vs.
healthy controls)
Healthy
controls
(n=162)
Psoriasis
patients
(n=146)
Psoriasis
patients with
BMI2 o30
(n=75)
Psoriasis
patients with
BMI2 X30
(n=73)
Fold change
(lesional vs.
non-lesional) P-value
False
discovery
rate
Non-
lesional
skin
Lesional
skin
S100A12 ENRAGE 4.06 1026 2.30 25.46 58.55 55.94 60.22 889.1 o1020 o1020 2.72 12.52
ACPP Prostatic acid
phosphatase
1.17 1035 2.50 0.20 0.49 0.46 0.51 8.3 o1020 o1020 8.87 11.92
CCL22 MDC o1050 3.03 409.31 1240.06 1227.13 1211.61 3.91 1.111016 1.181015 8.93 10.90
IL1RN IL1RA 5.67 1032 2.65 68.97 182.84 138.65 223.63 3.03 2.861011 1.651010 3.93 5.53
TNPO1 MIP1b 1.52 1039 2.34 131.53 307.87 299.36 314.43 2.82 o1020 o1020 8.51 10.01
CCL2 MCP1 o1040 3.55 141.20 501.78 491.29 509.71 2.47 o1020 o1020 10.39 11.70
VEGFA VEGF 1.74 1029 1.83 449.19 821.76 859.10 794.82 1.99 9.761013 6.611012 8.86 9.85
ICAM1 ICAM1 1.67 1005 1.26 134.07 169.41 153.51 184.43 1.84 7.741008 3.171007 6.68 7.56
IL15 IL-15 8.80 1006 1.25 0.65 0.81 0.80 0.81 1.84 1.851009 8.861009 6.69 7.57
TNFRSF1B TNF-RII 7.321018 1.40 3.50 4.91 4.60 5.21 1.53 5.451008 2.261007 8.94 9.55
TNF TNFa o1050 2.50 3.54 8.85 8.37 9.31 1.453 1.251008 5.511008 3.11 3.65
CXCL5 ENA78 1.40 1045 3.04 0.75 2.29 2.08 2.48 1.144 3.251002 6.281002 2.25 2.44
Abbreviations: BMI, body mass index; FDR, false discovery rate; RT-PCR, real-time reverse transcriptase PCR.
1P-values were adjusted to control the FDR and all resulted in FDR o0.05.
2BMI defined as baseline BMI o30 includes normal and overweight patients; BMI defined as baseline BMI X30 includes obese patients.
3TNF has previously been reported to be increased in psoriatic lesional skin when assessed via by RT-PCR (Sua´rez Farin˜as et al., 2010).
4CXCL5/ENA78 has previously been reported to be increased in psoriatic lesional skin (Zhou et al., 2003).
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involving CTLA4 signaling is one of the mechanisms for the
therapeutic action of psoralen plus long-wave UV, a well-
established psoriasis treatment (Singh et al., 2010). TLR3 has
a fundamental role in pathogen recognition and activation of
innate immunity and is expressed in the keratinocytes of
normal, non-lesional and psoriatic skin, and on monocyte-
derived dendritic cells (Baker et al., 2003). The interaction of
TLR3 with its ligand can yield keratinocyte activation and the
release of proinflammatory cytokines TNF and IL-8 (Begon
et al., 2007), and TLR3 signaling generally activates
numerous IFN- and TNF-stimulated gene products that are
also upregulated in psoriasis. However, because of the
extensive overlap in regulated genes, activation of signaling
by TLR3 cannot be definitively determined.
Given that psoriasis is increasingly recognized to be
associated with comorbid conditions of obesity, diabetes,
metabolic dysregulation, and cardiovascular diseases that
may be related to inflammation in skin (Davidovici et al,
2010), it is of interest that associated functional pathways
were also identified through IPA, including metabolic disease
and cardiovascular disease (Supplementary Figure S1b on-
line), leading to two potential mechanisms for increased
association between psoriasis and metabolic and cardiovas-
cular comorbidities. First, a product made in psoriatic
plaques could produce diffusible hormone-like proteins that
influence the biology of distant cells/tissues (e.g., renin,
vascular endothelial growth factor and monocyte chemoat-
tractant 9 protein-1 (CCL2); Table 4). Second, the IPA findings
show dysregulated gene expression in psoriasis lesions in
metabolic pathways associated with atherosclerosis, PPARa
and RAR activation, renin–angiotensin signaling, leptin
signaling, and others that may be important in comorbid
conditions (Supplementary Figure S1d online). These net-
works imply activated transcription factors underlying ob-
served changes with the interesting suggestion that activation
of NROB2 could relate to suppressed PPARg and RAR
network alterations. Another example is the cytochrome C
oxidase family (COX5A, COX7A1, and COX15), which is
associated with mitochondrial dysfunction and in turn is
regulated by nitric oxide (NO) signaling. Given the genetic
association of psoriasis with inducible NO synthase (Stuart
et al., 2010) and increased expression of these NO-forming
enzymes in this disease (Lowes et al., 2005), the gene
expression pattern seen in psoriatic skin may reflect
cellular dysfunction at other sites that could be governed by
common regulatory pathways such as the NO response.
Endothelial cell function is both intermediately related to NO
metabolism and dysfunctional in psoriasis patients (Karadag
et al., 2010). Although resting vascular tone is largely
regulated by endothelial NO synthase (Naber et al., 2001),
we note that alterations in vascular NO metabolism have
been previously associated with inflammation. Thus, one
might speculate that alterations in constitutive versus
inducible NO synthesis in tissues outside the skin could
potentially alter endothelial/vascular function and lead to
cardiovascular disease (Grassi et al., 2011). The skin changes
may offer a window into systemic cellular metabolism that
cannot be directly assessed. Given that we studied patients
across a range of BMIs, some gene expression associated with
higher BMI (X30) might have been present. However,
analyses by BMI subgroups did not detect any significant
difference, and inclusion of BMI as a covariate in the analysis
neither yielded significant findings nor altered analysis
outcomes.
In conclusion, this evaluation of the psoriasis transcrip-
tome, the largest study to date, to our knowledge, to assess
global gene expression and serum protein profiling in a
relatively homogenous group of patients with moderate-to-
severe psoriasis not receiving systemic psoriasis therapy
provides additional support for inflammation-related patho-
genic mechanisms in psoriasis. This study also provides
previously unreported insights into the biological changes
that occur in lesional skin of patients with moderate-to-severe
psoriasis as they relate to systemic psoriatic manifestations
and comorbidities (i.e., cardiovascular disease and metabolic
syndrome). Evaluating patients with uniformly severe disease
appears to have enabled detection of previously unidentified
metabolic/cardiovascular risk pathways, particularly because
cardiovascular risk is more highly associated with extensive
disease (Gelfand et al., 2006; Mehta et al., 2010). Ultimately,
risk pathways must be reconciled with specific genes
involved to derive meaningful associations that can serve as
tools for future therapeutic targets and, hence, may even-
tually lead to prevention of psoriasis comorbidities. The
utilization of large patient cohorts to develop disease profiles
from multiple matrices will continue to significantly con-
tribute to the understanding of the pathophysiology of disease
and associated comorbidities.
MATERIALS AND METHODS
Further details are provided in the Supplementary Materials and
Methods online.
Patients and tissue/serum samples
Skin punch biopsy samples were obtained from 89 patients with
histologically confirmed chronic psoriasis vulgaris who were
enrolled into an IRB-approved Phase 3, multicenter, randomized
trial protocol (ACCEPT trial; Griffiths et al., 2010). Patients entering
this trial were similar to those in other Phase 3 psoriasis studies in
that they were candidates for systemic treatment, had at least 10% of
body surface area affected by plaque psoriasis, and some may have
been treated previously with systemic agents. To enter the study,
patients could not have used topical agents for 2 weeks before
treatment, nor could they have used systemic agents within 4 weeks
of the first treatment. In addition, they may not have used any
biological agent within 3 months of the first administration
of study agent or within five times the half-life of the biological
agent before the first administration of study agent, whichever
was longer. For each patient, baseline skin biopsies included
both lesional and macroscopically normal non-lesional skin samples
were collected. Lesional skin samples were isolated from a
representative psoriatic target lesion (X3 cm). Serum samples were
obtained from 162 healthy volunteers (Bioreclimation, Hicksville,
NY) with approved written informed consent and a subset of
149 patients, of which 62 were also a part of the biopsy substudy,
with psoriasis from the ACCEPT trial (Griffiths et al., 2010). This
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study was conducted in compliance with the Declaration of Helsinki
Principles.
RNA processing and microarray hybridization
Skin biopsies were snap-frozen in liquid nitrogen and stored at
801C until used. RNA was extracted using the Qiagen RNeasy
Fibrous Tissue Mini Kit (QIAGEN, Valencia, CA) and later
hybridized to GeneChip HG U133 Plus 2.0 (Affymetrix, Santa
Clara, CA). Raw data have been deposited in NCBI’s Gene
Expression Omnibus and are accessible through accession
number GSE 30999.
Statistical analysis
Succinctly, 3 samples were excluded from analysis because
of low quality control measures. Images were scrutinized for
spatial artifacts using Harslight (Sua´rez Farin˜as et al. 2005b).
Expression measures were obtained using GCRMA algorithm
(Wu et al., 2004) and changes in lesional versus non-lesional skin
were assessed using general linear model (Mardia et al., 1979;
Freund et al., 1986). P-values were adjusted for multiple hypotheses
using the Benjamini–Hochberg procedure (Benjamini and Hochberg,
1995). Transcripts with low expression were excluded. Genes
showing FCH42 and FDRo0.05 were considered to be part of
the disease profile.
RT-PCR testing
Applied Biosystems (Foster City, CA) Taqman 16-gene and 48-gene
low-density array cards were used for RT-PCR analysis. The 16-gene
cards were tested on 13 healthy/normal and 20 pairs of
psoriasis non-lesional and lesional skin biopsy samples. The 48-
gene cards were tested on 12 healthy/normal and 43 pairs of
psoriasis skin biopsy samples. Probe set identifications are provided
in Supplementary Table S6 online. The resulting data were normal-
ized to human acidic ribosomal protein expression (Gene Symbol:
RPLPO).
Serum protein profiling
A 92-protein vendor-defined multiplex Luminex-based panel (Hu-
man Map 1.6 plus IL-17 and IL-23; Rules Based Medicine, Austin,
Texas) was used to profile differential serum protein expression from
healthy volunteers (n¼ 162) and patients with psoriasis (n¼ 149).
The complete list of analytes in the Human Map 1.6 can be found
at http://rulesbasedmedicine.com/products-services/humanmap-ser-
vices/human-discoverymap.
Immunohistochemistry
Frozen tissue sections from normal, psoriatic lesional, and non-
lesional skin (n¼ 5) were stained with mouse monoclonal antibodies
for renin (AbD Serotec, Planegg, Germany (10 mg)), CTLA4 (Abcam,
Cambridge, MA (1:100)) and TLR3 (Abcam(1:10)). Standard proce-
dures were employed as previously described (Fuentes-Duculan
et al., 2010).
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